

HPV Prevention and Control Board

Short introduction at the first HPV Prevention and Control Board meeting in Antwerp 27-28 June 2016



HPV Prevention
and Control Board

www.hpvboard.org

Unique expertise: inspired on the Viral Hepatitis Prevention Board (VHPB)

- Embedded in the same facilities (University of Antwerp, Centre for the Evaluation of Vaccination)
- Based on a similar way of working
- Same scientific secretariat team
- More than 23 years of support to the control and prevention of Viral Hepatitis in Europe:
 - Support implementation of WHO recommendations related to Viral Hepatitis
 - Organising discussion forum and meetings (very fast if needed) with experts on Viral Hepatitis
 - Rapid response on Viral Hepatitis issues that can affect public health
 - Coordination between organisations working on Viral Hepatitis
- Network of advisors in the broad field of Viral Hepatitis
- Dissemination platform





Recent meetings

- ▶ 2016 March, Ljubljana, Slovenia
- ▶ 2015 November Riga, Latvia
- ▶ 2015 June London, UK

Recent publications

- ▶ Global progress in the control of viral hepatitis and acceptable delay in Hepatitis B immunization
Human Vaccines & Immunotherapeutics 2016, DOI:10.1080/21645515.2016.1177689
- ▶ Long-term Protection After Hepatitis B Vaccine
J Infect Dis. 2016, doi: 10.1093/infdis/jiv750

Recent newsletters

- ▶ Prevention and control of viral hepatitis in the Baltic States: lessons learnt and the way forward
- ▶ Towards a hepatitis-free Europe: how to make it feasible and affordable
- ▶ Burden and prevention of viral hepatitis in Arctic region

News - World Health Assembly (WHA) endorsed WHO's first Global Health Sector Strategy on viral hepatitis for 2016-2021

On 28 May 2016, representatives from the WHO Member States convening the Sixty-ninth World Health Assembly unanimously endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis for 2016-2021.

Aim of the strategy: spur countries to action in order to eliminate hepatitis as a public health threat by 2030.

[More info](#)



[Read more](#)

News - May is Hepatitis Awareness Month

In the United States, May is Hepatitis Awareness Month. The 19th of May is Hepatitis Testing Day.

For more info:

- [CDC hepatitis website](#)
- [follow on twitter](#)



[Read more](#)

News - Report on Innovative Financing into Hepatitis B and C Prevention and Treatment in Low and Middle Income Countries.

VHPB launches report on Innovative Financing into Hep B and C Prevention and Treatment.

Download the:

- [Press release](#)
- [Infographic](#)
- [Report](#)

Read the blog:

- [Eliminating a 'silent killer': innovative sources of financing to help meet costs of prevention and treatment of viral hepatitis](#) by Pierre Van Damme.



Mission, goal & Objectives

1. Mission:

Generate, multiply and disseminate relevant information on HPV to a broad array of stakeholders.

2. Goal:

Contribute to the control of HPV infection and to the prevention and screening of HPV related cancers.

3. Objectives:

Providing evidence based guidance on key technical and strategic issues.

Monitoring the progress of HPV control programs at the country and regional levels.





HPV Prevention
and Control Board

www.hpvboard.org

STRUCTURE

A multi-disciplinary Board formed by prominent experts (called *Advisors*)

- Act in their personal capacity, and not as representatives of their institutions
- Are often affiliated with stake holding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president etc : minimal bureaucratic structure

Advisors:

- Marc Arbyn
- Paolo Bonanni
- Xavier Bosch
- Kate Cuschieri
- Silvia de Sanjosé
- Joakim Dillner
- Eduardo Franco
- Mark Kane
- Susanne Krüger Kjaer
- Mira Kojouharova
- Heidi Larson
- Pier Luigi Lopalco
- Lauri Markowitz
- Liudmila Mosina/Nedret Emiroglu
- Mario Poljak
- Margaret Stanley
- Pierre Van Damme
- Alex Vorsters
- Susan Wang




Supported by a permanent & dynamic **Scientific Secretariat:**

- ✓ Team members
 - ✓ Emmy Engelen, Brenda Janssens
 - ✓ Greet Hendrickx
 - ✓ Ina Lodewyckx
 - ✓ Alex Vorsters
- ✓ Executive Secretary: Pierre Van Damme
- ✓ Located withing the facilities of the Centre for the Evaluation of Vaccination (CEV), University of Antwerp
- ✓ Independent from:
 - International organisations like WHO/ECDC/EU
 - Ministries of health
 - Professional and scientific societies
 - Industry



Secretariat implements:

- Preparation and organisation of meetings
 - Publications
 - Media activities
 - Website: www.hpvboard.org
 - Participation in third party meetings
 - All financial issues are done by the rules of the University of Antwerp
-  Permanent intensive communication between HPV board members and secretariat





HPV Prevention
and Control Board

www.hpvboard.org

ACTIVITIES

Two meetings per year

1. Technical meeting (topics: future vaccines, vaccine strategies, booster doses, health economics, screening technologies and strategies, vaccine safety, dealing with anti-vaccine messages, et cetera)
2. Country meeting: SWOT analysis of a country or a region



Output of the meetings published:

- international scientific journals
- [HPV Prevention & Control Board website](#)



Why a HPV Prevention and Control Board?

With the achievements of decades of work on epidemiology, vaccines and test development, clinical trials, and new screening tools coming into public health and clinical use, the past years have been an exciting time for the Human Papilloma Virus (HPV) prevention community. High income countries and some middle income countries have begun routine use of the HPV vaccine and the newer screening tests in various ways, even low income countries are beginning to establish pilot programs made possible with GAVI funding and dramatically lower prices of vaccine for GAVI eligible countries.

Because of the availability of techniques that facilitate access to prevention, screening and treatment, we believe there is great value added in the establishment of an independent international multidisciplinary HPV prevention and control Board of top experts in the field. Experts who provide evidence based reflection and guidance on strategic, technical, and policy issues that will occur as we move forward in the implementation of our control programs.

The HPV Board will assist in the monitoring and evaluation of national and regional control programs in support of Partners such as World Health Organization (WHO), Centre for Disease control (CDC), and Global Alliance for Vaccine and immunization (GAVI).

Follow HPVBoard



Subscribe to our newsletter

Kick off 1-2/12/2015

Contact

HPV Prevention and Control
Board
Executive Secretariat

University of Antwerp
Campus Drie Eiken, R 2.18
Universiteitsplein 1
2160 Wilrijk
Belgium
Tel. +32 (0)3 265 26 64
Fax info[at]hpvboard.org

About us

- > Mission statement
- > History
- > Structure
- > Supports and grants
- > Review cycle

Meetings

- > Presentations

News & Ressources

- > HPV Board Newsletter
- > Journals and newsletters
- > Reports
- > Guidellines from international organisations

Vaccine safety

- > Vaccine Safety Net



HPV Prevention and Control Board Kick off, 1-2 December 2015



27-28 June Meeting (Antwerp): Barriers in HPV Vaccination & cervical screening programmes

Objectives:

- Review barriers that impact vaccination and screening programmes.
- Review adverse events following HPV vaccination.
- Update viewpoints regarding safety issues and describe new developments.
- Discuss the impact of safety issues and crises in an international perspective.
- Review factors impacting adherence to cervical screening programmes.
- Learn from country initiatives.
- Propose strategies to counter vaccination and screening hesitancy and to build public confidence.



27-28 June Meeting (Antwerp): Barriers in HPV Vaccination & cervical screening programmes

Short programme:

- Session 1: Interpretation of vaccine safety data
- Session 2: Vaccine confidence
- Session 3: Vaccination programmes: country experiences
- Session 4: Barriers & opportunities in HPV screening
- Session 5: HPV-faster, broadening the scope for prevention of HPV-related cancer
- Session 6: Conclusions

